| 1.5 0.07 (4.9%) | 05-08 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.84 | 1-year : | 2.1 |
| Resists | First : | 1.57 | Second : | 1.79 |
| Pivot price | 1.48  |
|||
| Supports | First : | 1.22 | Second : | 1.01 |
| MAs | MA(5) : | 1.45 |
MA(20) : | 1.53 |
| MA(100) : | 1.82 |
MA(250) : | 1.48 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 29.8 |
D(3) : | 24.3 |
| RSI | RSI(14): 49.6 |
|||
| 52-week | High : | 3.06 | Low : | 0.48 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IVVD ] has closed below upper band by 44.4%. Bollinger Bands are 43% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.53 - 1.54 | 1.54 - 1.55 |
| Low: | 1.42 - 1.43 | 1.43 - 1.44 |
| Close: | 1.49 - 1.5 | 1.5 - 1.52 |
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
Sat, 09 May 2026
Number of shareholders of Invivyd, Inc. – NASDAQ:IVVD - TradingView
Thu, 07 May 2026
Invivyd sets May 14 webcast for quarterly results and business update - Stock Titan
Tue, 05 May 2026
Invivyd gives 17 new hires options to buy 731,000 shares - Stock Titan
Fri, 24 Apr 2026
Invivyd (IVVD) Announces Favorable Phase 3 Analysis for VYD2311 COVID-19 Treatment - Yahoo Finance
Fri, 10 Apr 2026
Invivyd: Why The Trial Upsizing Isn't The Green Light Bulls Think It Is (NASDAQ:IVVD) - Seeking Alpha
Thu, 09 Apr 2026
Invivyd stock surges 25% on COVID-19 trial progress - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 283 (M) |
| Shares Float | 168 (M) |
| Held by Insiders | 7.3 (%) |
| Held by Institutions | 92.2 (%) |
| Shares Short | 29,260 (K) |
| Shares Short P.Month | 24,530 (K) |
| EPS | -0.31 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.86 |
| Profit Margin | -98.3 % |
| Operating Margin | -73 % |
| Return on Assets (ttm) | -17.1 % |
| Return on Equity (ttm) | -34 % |
| Qtrly Rev. Growth | 24.5 % |
| Gross Profit (p.s.) | 0.17 |
| Sales Per Share | 0.18 |
| EBITDA (p.s.) | -0.2 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -58 (M) |
| Levered Free Cash Flow | -38 (M) |
| PE Ratio | -5 |
| PEG Ratio | 0 |
| Price to Book value | 1.74 |
| Price to Sales | 7.93 |
| Price to Cash Flow | -7.3 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|